Intellia Therapeutics Inc (NTLA) Stock Analysis

Intellia Therapeutics Inc (NTLA) is a publicly traded company in the HEALTHCARE sector. It trades at $13.13, carries a market capitalization of $1.92B. This page summarizes the public market data, fundamentals, and frequently asked questions for NTLA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Intellia Therapeutics Inc currently has a Bullish sentiment score of 0.54.

About Intellia Therapeutics Inc

Intellia Therapeutics, Inc. (NTLA) is a pioneering gene editing company based in Cambridge, Massachusetts, specializing in the development of transformative therapies for genetic disorders using its proprietary CRISPR/Cas9 technology. The company is advancing a diverse pipeline of innovative treatment candidates currently in clinical trials, underscoring its commitment to precision medicine. As a frontrunner in the gene editing landscape, Intellia benefits from a strong intellectual property ...

GNG Research Analysis

GNG Research scores Intellia Therapeutics Inc (NTLA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for NTLA.

Frequently Asked Questions

Does NTLA pay dividends?

Intellia Therapeutics Inc (NTLA) does not currently pay a regular dividend.

What is NTLA's market cap?

Intellia Therapeutics Inc (NTLA) has a market capitalization of $1.92B with a current stock price of $13.13.